Primary Country (Mandatory)

Other Country (Optional)

Set News Language for United States

Primary Language (Mandatory)
Other Language[s] (Optional)
No other language available

Set News Language for World

Primary Language (Mandatory)
Other Language(s) (Optional)

Set News Source for United States

Primary Source (Mandatory)
Other Source[s] (Optional)

Set News Source for World

Primary Source (Mandatory)
Other Source(s) (Optional)
  • Countries
    • India
    • United States
    • Qatar
    • Germany
    • China
    • Canada
    • World
  • Categories
    • National
    • International
    • Business
    • Entertainment
    • Sports
    • Special
    • All Categories
  • Available Languages for United States
    • English
  • All Languages
    • English
    • Hindi
    • Arabic
    • German
    • Chinese
    • French
  • Sources
    • India
      • AajTak
      • NDTV India
      • The Hindu
      • India Today
      • Zee News
      • NDTV
      • BBC
      • The Wire
      • News18
      • News 24
      • The Quint
      • ABP News
      • Zee News
      • News 24
    • United States
      • CNN
      • Fox News
      • Al Jazeera
      • CBSN
      • NY Post
      • Voice of America
      • The New York Times
      • HuffPost
      • ABC News
      • Newsy
    • Qatar
      • Al Jazeera
      • Al Arab
      • The Peninsula
      • Gulf Times
      • Al Sharq
      • Qatar Tribune
      • Al Raya
      • Lusail
    • Germany
      • DW
      • ZDF
      • ProSieben
      • RTL
      • n-tv
      • Die Welt
      • Süddeutsche Zeitung
      • Frankfurter Rundschau
    • China
      • China Daily
      • BBC
      • The New York Times
      • Voice of America
      • Beijing Daily
      • The Epoch Times
      • Ta Kung Pao
      • Xinmin Evening News
    • Canada
      • CBC
      • Radio-Canada
      • CTV
      • TVA Nouvelles
      • Le Journal de Montréal
      • Global News
      • BNN Bloomberg
      • Métro
Abortion pill opponents appear to get favourable hearing at U.S. appeals court

Abortion pill opponents appear to get favourable hearing at U.S. appeals court

Global News
Thursday, May 18, 2023 12:34:35 AM UTC

The closely watched case is likely to wind up at the U.S. Supreme Court, which already intervened to keep mifepristone available while the legal fight winds through the courts.

Federal appeals court judges on Wednesday appeared to express support for opponents of the abortion pill mifepristone to pursue their challenge to its U.S. approval, which has potentially far-reaching consequences for abortion access across the country.

From the start of the high-stakes oral arguments before the 5th U.S. Circuit Court of Appeals in New Orleans, all three judges on the panel repeatedly pressed lawyers for the U.S. government and Danco Laboratories, which sells the drug under the brand name Mifeprex.

Circuit Judge James Ho interrupted the government’s attorney, Sarah Harrington, almost as soon as she began her presentation, questioning her use of “unprecedented” to describe the case.

“I guess I’m just wondering why not just focus on the facts of this case rather than have this sort of ‘FDA can do no wrong’ theme,” Ho said.

The judges appeared skeptical of the government’s and Danco’s views that the doctors and organizations who brought the lawsuit could not sue because they have not been harmed by the U.S. Food and Drug Administration approval of the drug in 2000.

The government and Danco want the panel to overturn last month’s ruling by U.S. District Judge Matthew Kacsmaryk in Amarillo, Texas suspending mifepristone’s approval.

The challenge to the drug’s availability comes as Republican-led states have enacted an increasing number of abortion bans and restrictions since the U.S. Supreme Court in June overturned its landmark 1973 Roe v. Wade decision that had legalized the procedure nationwide.

Anti-abortion groups and doctors, led by the recently formed Alliance for Hippocratic Medicine, defended Kacsmaryk’s order during Wednesday’s argument. They claimed in their lawsuit last year that mifepristone is unsafe and that the FDA’s approval of it was illegal.

Read full story on Global News
Share this story on:-
More Related News
Alberta mother prepares to welcome ‘miracle’ quadruplets

Darlene Hensch, who once struggled with unexplained infertility, is now expecting quadruplets and preparing for a high-risk delivery and life-changing journey.

Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talks

Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving forward.

A ring with an extra carrot ends decades-long mystery for Alberta couple

They've been married for 55 years, but for most of that time, something has been missing from Janet and Robert Cockwill's life, until their grandson made a remarkable discovery.

Liberals are being ‘dishonest’ about future of pharmacare, NDP says

NDP interim leader Don Davies said the government's response to a commissioned report on the program was 'shockingly dismissive,' and the health minister has not committed to act.

Ontario government routinely ignoring environmental consultations, AG finds

The Ford government is routinely making decisions before environmental consultations have concluded and under-resourcing public education about those consultations, the AG found.

Vacancies for nurses, support workers tripled since 2016, StatCan finds

From 2016 to 2024, the vacancy rate for health-related occupations nearly tripled, increasing from 2.1 per cent to 5.8 per cent, the report said.

Alberta’s Smith vows to keep up fight against Ottawa despite pipeline pact

The milestone deal with Ottawa signed earlier this week clears regulatory hurdles for a potential pipeline from Alberta to the West Coast. 

‘Frustrating’: Veterinarians urge regulatory changes as medicine shortages mount

Canadian veterinarians are sounding the alarm about their loss of access to about 40 per cent of medications they once were able to use and they are blaming Health Canada.

© 2008 - 2025 Webjosh  |  News Archive  |  Privacy Policy  |  Contact Us